Does India Pharma Inc need a new blueprint?
The open letter from nine EU pharma leaders and China’s new five year pharma plan are the latest and clearest signals that the…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
The double burden of tighter enforcement, slower implementation
India’s pharma MSMEs are facing a tough transition to revised GMP norms, hampered by slow implementation of the very schemes that…
Diversifying beyond the US market
India's next export wave will not be won on tariff advantage alone; mutual recognition of standards and regulatory cooperation…
The fine line between reform and risk
A couple of recent notifications, one a notified amendment and the second one, a proposed amendment, concerning medicines have…
India Pharma’s new resilience mantras
As geopolitical disruptions, increasing ESG pressures and shifting supply chains become the new normal, Indian pharma companies…
Sun Pharma bets on Organon for its next wind
Sun Pharma’s $12 billion acquisition of Organon will prove to be a milestone as the largest takeover by an Indian pharma company.…
Midst global headwinds, CDSCO cracks down on GLP-1 gold rush
As pharma companies deal with price wars, increasing regulatory heat and a volatile geopolitical situation, navigating this…
Building India Pharma Inc’s innovation muscle
While we agree that “what got us here (an affordable generics powerhouse) will not get us there (a leader in pharma innovation)”,…
India-EU FTA offers new hope
The signing of the India-EU Free Trade Agreement after almost two decades of negotiations is being hailed as the ‘mother of all…
Balancing protection and compliance
2026 must be the year India’s pharma policy and industry align, as policy directives can only be successful if all sections of the…
A biosimilar boost amid trade barriers
Even as India’s biggest pharma companies pursue biosimilars, product recalls related to manufacturing defects threaten to queer…
Will India pass the cough syrup trust test this time?
While India’s CDMOs are well positioned to capitalise on the booming GLP-1 market, the recurring episodes of contaminated cough…
Turning the tariff tight spot into a sweet spot
US President Trump's fresh salvo of 100 per cent tariffs on branded or patented pharmaceutical products not ‘Made in America’…
Tariff turbulence sparks a reset
India’s pharma sector is rewriting its global playbook pivoting to other markets like the EU, Africa and other geographies with…
Walking the talk on ESG, workplace safety
Proactively investing in employee and workplace safety is not just good for employees, but makes smart business sense
The promise and perils of weight loss drugs
Doctors have warned of the risk of overuse and misuse, cautioning that patients will see such medications as an easy, quick fix,…
What US FDA’s new surprise foreign inspections plan means for India
Pharma companies exporting to the US should now rightly be on guard and start preparing for the inevitable “knock on the factory…
How counterfeiters are breaching India’s QR code system
If the QR code system is not all that it was promised to be, what are the next steps to safeguard our medicines?
US tariffs, IP issues threaten patient access
The judgements on the Roche Natco case for SMA medicine risdiplam could impact petitions from patients suffering from other rare…
Balancing MAGA and MIGA
While the PILLS Act, aims for “strategically incentivising reshoring of essential medicines” to the US, India Pharma Inc cannot do…